For six years, the Multiple Sclerosis Association of America (MSAA) has been honored to host our annual Improving Lives Benefit in-person, raising funds for the MS community. Now, MSAA is excited to bring our community “Together at Home” for our first-ever virtual Improving Lives Benefit, showcasing more than 50 years of hope, impact, and support […]
Read News ArticleCategory: Latest News
What’s New in MS Research: March 2021
The first quarter of 2021 has been marked by welcome news on the medical front, and those hopeful developments aren’t limited to the increasing number of COVID-19 vaccinations being given across the country. Significant strides in treating and understanding MS also have been made in these early months of the year, as detailed in this edition of “What’s New in MS Research.”
Read News ArticleFDA Approves Ponvory™ for the Treatment of Relapsing Forms of MS
Updated: March 25, 2021 to include patient assistance resource information Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the United States Food and Drug Administration (FDA) approved Ponvory™ (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including […]
Read News ArticleThe Multiple Sclerosis Association of America (MSAA) Focuses on Improving Mental Health and Wellness in Honor of MS Awareness Month
The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. MSAA is proud to announce the 2021 awareness campaign theme on Improving Mental Health and Wellness, with specific programs addressing Purpose in Life, depression and anxiety in MS, care partnering, and wellness strategies to improve symptom management and overall quality […]
Read News ArticleWhat’s New in MS Research: January 2021
The expression, “Here’s hoping this year is better than the last” has particular poignancy as we transition into 2021. Happily, much of the recent news regarding multiple sclerosis (MS) provides cause for considerable hope, as reflected in the study results and other reports featured in this month’s iteration of “What’s New in MS Research.”
Read News ArticleImpact Education, LLC and MSAA Release New Whitepaper on Payer Considerations for Providing Support to People With MS and Their Care Partners
BLUE BELL, Pa.–(BUSINESS WIRE)–Impact Education, LLC (IMPACT) and the Multiple Sclerosis Association of America (MSAA) announce the release of a new whitepaper based on key findings from a series of dynamic roundtable discussions between payers and multiple sclerosis (MS) healthcare providers. MS affects about 1,000,000 people in the United States and while quality care is […]
Read News ArticleWhat’s New in MS Research: November 2020
While we all know “MS” stands for “multiple sclerosis,” with so much exciting research reported in this edition of “What’s New in MS Research,” we can almost imagine that “MS” could also refer to the quest for “multiple solutions” in MS. Although a great deal of the research looks to further understand the biology, easing the symptoms, and slowing or stopping the physical damage of MS, the studies and other information presented here are very encouraging – and they are only a small sample of the vast array of research under way around the world.
Read News ArticleWhat’s New in MS Research: September 2020
This edition of MSAA’s “What’s New in MS Research” article features highlights from the annual meetings of the American Academy of Neurology (AAN) and the Consortium of MS Centers (CMSC). Because of the ongoing COVID-19 pandemic, both of these meetings were held virtually. While not all of the reports are positive, the good far outweighs the rest, and encompasses not only promising research advances in MS, but also a potential role for a long-established DMT in treating COVID-19.
Read News ArticleFDA Approves Kesimpta® (Ofatumumab), the First Self-Administered B-cell Therapy for Relapsing Forms of MS
Updated September 3, 2020 Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 20, 2020, Novartis announced that the United States Food and Drug Administration (FDA) approved Kesimpta® (ofatumumab) for adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease. Kesimpta is a […]
Read News ArticleFDA Approves Generic Version of Tecfidera®, Taken Orally for MS
Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 17, 2020, the United States Food and Drug Administration (FDA) awarded early approval of Mylan’s generic version of Biogen’s Tecfidera® (dimethyl fumarate), an oral medication approved in 2013 for relapsing forms of MS in adults. Mylan announced the launch of this generic medication […]
Read News Article